Bifidobacterium animalis subsp. lactis HN019

Bifidobacterium animalis subsp. lactis HN019 is a clinically studied probiotic strain that produces short-chain fatty acids and bacteriocins to restore gut microbiota balance. This strain enhances immune function through increased IgA antibody production and reduces IBS symptoms by modulating the gut-brain axis.

Origin & History

Bifidobacterium animalis subsp. lactis HN019 is a well-researched probiotic strain derived from dairy. It is known for its robust ability to survive the digestive tract and confer health benefits.

Historical & Cultural Context

This strain has been utilized in functional foods and dietary supplements due to its well-documented health benefits and stability in various formulations.

Health Benefits

- Supports digestive health by enhancing gut microbiota balance, reducing symptoms of IBS by up to 50%. - Enhances immune function by increasing the production of IgA antibodies, which are crucial for pathogen defense. - May improve nutrient absorption by increasing the surface area of the intestinal lining, leading to better assimilation of vitamins and minerals. - Reduces inflammation by modulating cytokine production, which can decrease the risk of chronic diseases. - Promotes regularity by increasing stool frequency and consistency, aiding those with constipation. - Supports mental health by producing short-chain fatty acids that influence brain function, potentially reducing anxiety and depression. - Enhances lactose digestion by producing lactase, helping those with lactose intolerance enjoy dairy products.

How It Works

B. animalis subsp. lactis HN019 adheres to intestinal epithelial cells via specific adhesins and produces antimicrobial compounds including acetate and lactate. The strain stimulates Peyer's patches to increase secretory IgA production and modulates cytokine expression by activating Toll-like receptor 2 pathways. It also enhances tight junction proteins like claudin-1 and occludin to strengthen intestinal barrier function.

Scientific Research

Numerous studies have demonstrated the efficacy of Bifidobacterium animalis subsp. lactis HN019 in improving gut health and immune responses, making it one of the most studied probiotic strains.

Clinical Summary

Randomized controlled trials with 200-400 participants demonstrate that HN019 supplementation at 2-10 billion CFU daily significantly reduces IBS symptom severity scores by 40-50% over 4-12 weeks. Studies show increased fecal bifidobacteria levels and improved stool consistency within 2-4 weeks of supplementation. Clinical evidence indicates enhanced immune markers including 23% increased salivary IgA levels and improved vaccine response in elderly populations. The strain shows consistent survival through gastric acid with viable counts maintained at therapeutic levels.

Nutritional Profile

- High in viable probiotic cells. - Produces lactic acid and short-chain fatty acids. - Enhances the bioavailability of nutrients.

Preparation & Dosage

Typically consumed in doses of 1-10 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Galactooligosaccharides, Lactobacillus casei, Inulin

Safety & Interactions

B. animalis subsp. lactis HN019 is generally well-tolerated with mild gastrointestinal symptoms like bloating or gas occurring in less than 5% of users during the first week. No significant drug interactions have been reported, though immunocompromised individuals should consult healthcare providers before use. The strain is considered safe during pregnancy and lactation based on extensive safety data. Individuals with severe acute pancreatitis or compromised intestinal barrier should avoid probiotic supplementation.